Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter

被引:118
|
作者
Wong, Vincent Wai-Sun [1 ,2 ]
Petta, Salvatore [3 ]
Hiriart, Jean-Baptiste [4 ]
Camma, Calogero [3 ]
Wong, Grace Lai-Hung [1 ,2 ]
Marra, Fabio [5 ]
Vergniol, Julien [4 ]
Chan, Anthony Wing-Hung [6 ]
Tuttolomondo, Antonino [7 ]
Merrouche, Wassil [4 ]
Chan, Henry Lik-Yuen [1 ,2 ]
Le Bail, Brigitte [8 ,9 ]
Arena, Umberto [5 ]
Craxi, Antonio [3 ]
de Ledinghen, Victor [4 ,8 ]
机构
[1] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China
[3] Univ Palermo, Sez Gastroenterol, DiBiMIS, Palermo, Italy
[4] Bordeaux Univ Hosp, Ctr Invest Fibrose Hepat, Hop Haut Leveque, Pessac, France
[5] Univ Firenze, Dipartimento Med Sperimentale & Clin, Florence, Italy
[6] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China
[7] Univ Palermo, Sez Med Interna & Cardioangiol, DiBiMIS, Palermo, Italy
[8] Bordeaux Univ, INSERM U1053, Bordeaux, France
[9] Bordeaux Univ Hosp, Hop Pellegrin, Serv Pathol, Bordeaux, France
关键词
FibroScan; Liver stiffness measurement; Non-alcoholic fatty liver disease; Hepatic steatosis; Liver biopsy; Diagnostic accuracy; MAGNETIC-RESONANCE SPECTROSCOPY; CHRONIC HEPATITIS-B; TRANSIENT ELASTOGRAPHY; STIFFNESS MEASUREMENT; XL PROBE; HEPATOCELLULAR-CARCINOMA; NONALCOHOLIC STEATOHEPATITIS; NONINVASIVE ASSESSMENT; OBESE-PATIENTS; UNITED-STATES;
D O I
10.1016/j.jhep.2017.05.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Controlled attenuation parameter (CAP) can be performed together with liver stiffness measurement (LSM) by transient elastography (TE) and is often used to diagnose fatty liver. We aimed to define the validity criteria of CAP. Methods: CAP was measured by the M probe prior to liver biopsy in 754 consecutive patients with different liver diseases at three centers in Europe and Hong Kong (derivation cohort, n = 340; validation cohort, n = 414; 101 chronic hepatitis B, 154 chronic hepatitis C, 349 non-alcoholic fatty liver disease, 37 autoimmune hepatitis, 49 cholestatic liver disease, 64 others; 277 F3-4; age 52 +/- 14; body mass index 27.2 +/- 5.3 kg/m(2)). The primary outcome was the diagnosis of fatty liver, defined as steatosis involving >= 5% of hepatocytes. Results: The area under the receiver-operating characteristics curve (AUROC) for CAP diagnosis of fatty liver was 0.85 (95% CI 0.82-0.88). The interquartile range (IQR) of CAP had a negative correlation with CAP (r = -0.32, p < 0.001), suggesting the IQR-to-median ratio of CAP would be an inappropriate validity parameter. In the derivation cohort, the IQR of CAP was associated with the accuracy of CAP (AUROC 0.86, 0.89 and 0.76 in patients with IQR of CAP <20 [15% of patients], 20-39 [51%], and >= 40 dB/m [33%], respectively). Likewise, the AUROC of CAP in the validation cohort was 0.90 and 0.77 in patients with IQR of CAp <40 and >= 40 dB/m, respectively (p = 0.004). The accuracy of CAP in detecting grade 2 and 3 steatosis was lower among patients with body mass index >= 30 kg/m(2) and F3-4 fibrosis. Conclusions: The validity of CAP for the diagnosis of fatty liver is lower if the IQR of CAP is >= 40 dB/m. Lay summary: Controlled attenuation parameter (CAP) is measured by transient elastography (TE) for the detection of fatty liver. In this large study, using liver biopsy as a reference, we show that the variability of CAP measurements based on its interquartile range can reflect the accuracy of fatty liver diagnosis. In contrast, other clinical factors such as adiposity and liver enzyme levels do not affect the performance of CAP. (C) 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:577 / 584
页数:8
相关论文
共 50 条
  • [1] Controlled Attenuation Parameter (CAP) with the XL Probe of the FibroscanA®: A Comparative Study with the M Probe and Liver Biopsy
    de Ledinghen, Victor
    Hiriart, Jean-Baptiste
    Vergniol, Julien
    Merrouche, Wassil
    Bedossa, Pierre
    Paradis, Valerie
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (09) : 2569 - 2577
  • [2] Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease
    de Ledinghen, Victor
    Wong, Grace Lai-Hung
    Vergniol, Julien
    Chan, Henry Lik-Yuen
    Hiriart, Jean-Baptiste
    Chan, Anthony Wing-Hung
    Chermak, Faiza
    Choi, Paul Cheung-Lung
    Foucher, Juliette
    Chan, Carmen Ka-Man
    Merrouche, Wassil
    Chim, Angel Mei-Ling
    Le Bail, Brigitte
    Wong, Vincent Wai-Sun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (04) : 848 - 855
  • [3] Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
    Mikolasevic, Ivana
    Orlic, Lidija
    Franjic, Neven
    Hauser, Goran
    Stimac, Davor
    Milic, Sandra
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (32) : 7236 - 7251
  • [4] Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease
    Shalimar
    Kumar, Ramesh
    Rout, Gyanranjan
    Kumar, Rahul
    Yadav, Rajini
    Das, Prasenjit
    Aggarwal, Sandeep
    Gunjan, Deepak
    Saraya, Anoop
    Nayak, Baibaswata
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2020, 39 (01) : 32 - 41
  • [5] Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy
    Victor de Lédinghen
    Jean-Baptiste Hiriart
    Julien Vergniol
    Wassil Merrouche
    Pierre Bedossa
    Valérie Paradis
    Digestive Diseases and Sciences, 2017, 62 : 2569 - 2577
  • [6] Use of a controlled attenuation parameter for the diagnosis of non-alcoholic fatty liver disease
    Goncharov, Alexey A.
    Sasunova, Armida N.
    Pilipenko, Vladimir I.
    Isakov, Vasily A.
    TERAPEVTICHESKII ARKHIV, 2023, 95 (08) : 641 - 647
  • [7] Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease
    Shen, Feng
    Zheng, Rui-Dan
    Shi, Jun-Ping
    Mi, Yu-Qiang
    Chen, Guo-Feng
    Hu, Xiqi
    Liu, Yong-Gang
    Wang, Xiao-Ying
    Pan, Qin
    Chen, Guang-Yu
    Chen, Jian-Neng
    Xu, Liang
    Zhang, Rui-Nan
    Xu, Lei-Ming
    Fan, Jian-Gao
    LIVER INTERNATIONAL, 2015, 35 (11) : 2392 - 2400
  • [8] LIVER STEATOSIS ASSESSED BY CONTROLLED ATTENUATION PARAMETER (CAP) MEASURED WITH THE XL PROBE OF THE FIBROSCAN: A PILOT STUDY ASSESSING DIAGNOSTIC ACCURACY
    Sasso, Magali
    Audiere, Stephane
    Kemgang, Astrid
    Gaouar, Farid
    Corpechot, Christophe
    Chazouilleres, Olivier
    Fournier, Celine
    Golsztejn, Olivier
    Prince, Stephane
    Menu, Yves
    Sandrin, Laurent
    Miette, Veronique
    ULTRASOUND IN MEDICINE AND BIOLOGY, 2016, 42 (01): : 92 - 103
  • [9] Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience
    Stephan, Baumeler
    Wolfram, Jochum
    Jorg, Neuweiler
    Irina, Bergamin
    David, Semela
    SWISS MEDICAL WEEKLY, 2019, 149
  • [10] Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease
    Chan, Wah-Kheong
    Mustapha, Nik Raihan Nik
    Mahadeva, Sanjiv
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (07) : 1470 - 1476